MDxHealth Booth #1109
MDxHealth is a global healthcare company that delivers first-in-class molecular diagnostic solutions for urologic cancers. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
ConfirmMDx for Prostate Cancer helps identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. ConfirmMDx is the first epigenetic and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer. SelectMDx for Prostate Cancer is a urine-based molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection.
Learn more at www.mdxhealth.com
Brands: ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer